COVID-19 vaccine maker BioNTech on Monday raised the lower bound of its 2022 COVID-19 vaccine revenue guidance for the full year, citing demand for its adapted shots and higher prices.
Tag Archive for: Pfizer
U.S. drugmaker Pfizer Inc and its German partner BioNTech SE said on Friday their Omicron-tailored shot targeting the BA.4/5 subvariants produced a strong antibody response in humans than the original shot after one month.
German Chancellor Olaf Scholz announced an agreement on Friday to let expatriates in China use the COVID-19 vaccine from Germany’s BioNTech and pressed for Beijing to allow the shot to be made freely available to Chinese citizens.
The early-stage study, which is being sponsored by BioNTech, aims to evaluate the combination shot’s safety, tolerability and immunogenicity, or the ability to generate immune response.
Swiss drugs regulator Swissmedic said it had been informed by vaccination centers of the appearance of bubbles during the preparation of the updated vaccine from Pfizer and BioNTech targeting the original version of the coronavirus and the BA.1 Omicron variant that led to a record surge in cases last winter.
GlaxoSmithKline scored a pivotal Priority Review from the FDA for its respiratory syncytial virus (RSV) vaccine candidate for older adults, which will expedite regulatory evaluation of its clinical data.
Swiss drugs regulator Swissmedic said on Wednesday it is examining potential risks in connection with bubbles that appeared in vials of COVID-19 vaccine boosters retooled to target the Omicron variant of the coronavirus.
GSK beat third-quarter earnings forecasts on Wednesday and raised its 2022 estimate for the second time in four months, continuing its strong start as a standalone prescription medicine business since spinning off its consumer health unit.
Australia’s CSL Ltd. said on Wednesday it had struck a licensing deal with Arcturus Therapeutics Holdings Inc. that would help it gain access to the U.S. drug developer’s messenger RNA (mRNA) vaccine technology.
Pfizer Inc. on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations.
